Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
:PSTV
Total Valuation
Plus Therapeutics has a market cap or net worth of $20.34M. The enterprise value is $6.34M.
Market Cap$20.34M
Enterprise Value$6.34M
Share Statistics
Plus Therapeutics has 60,490,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,490,100
Owned by Insiders10.36%
Owned by Institutions0.21%
Financial Efficiency
Plus Therapeutics’s return on equity (ROE) is 1.45 and return on invested capital (ROIC) is 263.26%.
Return on Equity (ROE)1.45
Return on Assets (ROA)-1.96
Return on Invested Capital (ROIC)263.26%
Return on Capital Employed (ROCE)1.65
Revenue Per Employee277.33K
Profits Per Employee-618.00K
Employee Count21
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio-0.10
Price to Fair Value-8.53
Price to FCF-1.28
Price to Operating Cash Flow-0.20
PEG Ratio>-0.01
Income Statement
In the last 12 months, Plus Therapeutics had revenue of 5.82M and earned -12.98M in profits. Earnings per share was -1.95.
Revenue5.82M
Gross Profit4.97M
Operating Income-14.70M
Pretax Income-12.98M
Net Income-12.98M
EBITDA-8.40M
Earnings Per Share (EPS)-1.95
Cash Flow
In the last 12 months, operating cash flow was -12.21M and capital expenditures -654.00K, giving a free cash flow of -12.87M billion.
Operating Cash Flow-12.21M
Free Cash Flow-12.87M
Free Cash Flow per Share-0.21
Dividends & Yields
Plus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.32
52-Week Price Change-82.22%
50-Day Moving Average0.37
200-Day Moving Average0.95
Relative Strength Index (RSI)47.52
Average Volume (3m)49.41M
Important Dates
Plus Therapeutics upcoming earnings date is Aug 18, 2025, After Close (Confirmed).
Last Earnings DateMay 30, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Plus Therapeutics as a current ratio of 0.34, with Debt / Equity ratio of -0.17%
Current Ratio0.34
Quick Ratio0.34
Debt to Market Cap0.04
Net Debt to EBITDA-0.39
Interest Coverage Ratio-3.95
Taxes
In the past 12 months, Plus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Plus Therapeutics EV to EBITDA ratio is -9.48, with an EV/FCF ratio of -7.08.
EV to Sales0.00
EV to EBITDA-9.48
EV to Free Cash Flow-7.08
EV to Operating Cash Flow-7.55
Balance Sheet
Plus Therapeutics has $9.87M in cash and marketable securities with $40.00K in debt, giving a net cash position of -$9.83M billion.
Cash & Marketable Securities$9.87M
Total Debt$40.00K
Net Cash-$9.83M
Net Cash Per Share-$0.16
Tangible Book Value Per Share-$0.15
Margins
Gross margin is -116.81%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-116.81%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Plus Therapeutics is $11.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.75
Price Target Upside3571.88% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-14.43%
EPS Growth Forecast16.04%